Skip to main content
Top
Published in: World Journal of Surgery 11/2011

01-11-2011

Surgical Impact on Gastric Cancer with Locoregional Invasion

Authors: Kuan-Kai Lai, Wen-Liang Fang, Chew-Wun Wu, Kuo-Hung Huang, Jen-Hao Chen, Su-Shun Lo, Anna Fen-Yau Li

Published in: World Journal of Surgery | Issue 11/2011

Login to get access

Abstract

Background

The benefit of resection of gastric cancer with locoregional invasion is still under debate. This study aimed to investigate the impact of surgery on patients with gastric cancer with locoregional invasion.

Methods

From January 1988 to December 2009, a total of 2,678 patients with gastric cancer underwent surgery at the Department of Surgery, Taipei Veterans General Hospital. Among these patients, 569 and 295 were diagnosed as T4a (serosa invasion without penetration of visceral peritoneum) and T4b (serosa exposure with invasion of adjacent structure), respectively. Invasion type and prognosis were analyzed in patients with gastric cancer who had either curative or palliative resection.

Results

Our results showed that patients with T4a gastric cancer had a better 5-year overall survival than patients with T4b (22.5% vs. 11.5%, P < 0.001). Patients with T4b who had curative resection had a better 5-year overall survival than those with T4b who had palliative resection (13.8% vs. 7.3%, P = 0.001). The prognosis of patients with gastric cancer with pancreas invasion was worse than those with mesocolon invasion, as no patients with pancreas invasion survived more than 5 years. Univariate and multivariate analyses showed that tumor size (P = 0.019), Bormann classification (P < 0.001), stromal reaction (P = 0.001), and nodal involvement (P < 0.001) were independent predictors for overall survival in patients with T4b gastric cancer.

Conclusion

Resection of T4b gastric cancer could be performed with curative intent. Patients with gastric cancer with pancreas invasion had a poorer prognosis than those with mesocolon invasion.
Literature
1.
go back to reference Department of Health (2008) Taiwan Public Health Report. Executive Yuan, R.O.C. (Taiwan) Department of Health (2008) Taiwan Public Health Report. Executive Yuan, R.O.C. (Taiwan)
2.
go back to reference Wu CW, Hsiung CA, Lo SS et al (2006) Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol 7:309–315PubMedCrossRef Wu CW, Hsiung CA, Lo SS et al (2006) Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol 7:309–315PubMedCrossRef
3.
go back to reference Hartgrink HH, van de Velde CJH, Putter H et al (2004) Extended lymph-node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. J Clin Oncol 22:2069–2077PubMedCrossRef Hartgrink HH, van de Velde CJH, Putter H et al (2004) Extended lymph-node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. J Clin Oncol 22:2069–2077PubMedCrossRef
4.
go back to reference Huang KH, Wu CC, Fang WL et al (2010) Palliative resection in noncurative gastric cancer patients. World J Surg 34:1015–1021PubMedCrossRef Huang KH, Wu CC, Fang WL et al (2010) Palliative resection in noncurative gastric cancer patients. World J Surg 34:1015–1021PubMedCrossRef
5.
go back to reference Martin RC 2nd, Jaques DP, Brennan MF et al (2002) Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg 236:159–165PubMedCrossRef Martin RC 2nd, Jaques DP, Brennan MF et al (2002) Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg 236:159–165PubMedCrossRef
6.
go back to reference Saito H, Tsujitani S, Maeda Y et al (2001) Combined resection of invaded organs in patients with T4 gastric carcinoma. Gastric Cancer 4:206–211PubMedCrossRef Saito H, Tsujitani S, Maeda Y et al (2001) Combined resection of invaded organs in patients with T4 gastric carcinoma. Gastric Cancer 4:206–211PubMedCrossRef
7.
go back to reference Kobayashi A, Nakagohri T, Konishi M et al (2004) Aggressive surgical treatment for T4 gastric cancer. J Gastrointest Surg 8:464–470PubMedCrossRef Kobayashi A, Nakagohri T, Konishi M et al (2004) Aggressive surgical treatment for T4 gastric cancer. J Gastrointest Surg 8:464–470PubMedCrossRef
8.
go back to reference Dhar DK, Kubota H, Tachibana M et al (2001) Prognosis of T4 gastric carcinoma patients: an appraisal of aggressive surgical treatment. J Surg Oncol 76:278–282PubMedCrossRef Dhar DK, Kubota H, Tachibana M et al (2001) Prognosis of T4 gastric carcinoma patients: an appraisal of aggressive surgical treatment. J Surg Oncol 76:278–282PubMedCrossRef
9.
go back to reference Kunisaki C, Akiyama H, Nomura M et al (2006) Surgical outcomes in patients with T4 gastric carcinoma. J Am Coll Surg 202:223–230PubMedCrossRef Kunisaki C, Akiyama H, Nomura M et al (2006) Surgical outcomes in patients with T4 gastric carcinoma. J Am Coll Surg 202:223–230PubMedCrossRef
10.
go back to reference Carboni F, Lepiane P, Santoro R et al (2005) Extended multiorgan resection for T4 gastric carcinoma: 25-year experience. J Surg Oncol 90:95–100PubMedCrossRef Carboni F, Lepiane P, Santoro R et al (2005) Extended multiorgan resection for T4 gastric carcinoma: 25-year experience. J Surg Oncol 90:95–100PubMedCrossRef
11.
go back to reference Maehara Y, Oiwa H, Tomisaki S et al (2000) Prognosis and surgical treatment of gastric cancer invading the pancreas. Oncology 59:1–6PubMedCrossRef Maehara Y, Oiwa H, Tomisaki S et al (2000) Prognosis and surgical treatment of gastric cancer invading the pancreas. Oncology 59:1–6PubMedCrossRef
12.
go back to reference Park JH, Hyung WJ, Choi SH et al (2010) Should direct mesocolon invasion be included in T4 for the staging of gastric cancer. J Surg Oncol 101:205–208PubMedCrossRef Park JH, Hyung WJ, Choi SH et al (2010) Should direct mesocolon invasion be included in T4 for the staging of gastric cancer. J Surg Oncol 101:205–208PubMedCrossRef
13.
go back to reference Ryu SY, Joo JK, Park YK et al (2008) Prognosis of gastric carcinoma invading the mesocolon. Asian J Surg 31:179–184PubMedCrossRef Ryu SY, Joo JK, Park YK et al (2008) Prognosis of gastric carcinoma invading the mesocolon. Asian J Surg 31:179–184PubMedCrossRef
14.
go back to reference An JY, Ha TK, Noh JH et al (2009) Proposal to subclassify stage IV gastric cancer to IVA, IVB and IVM. Arch Surg 144:38–45PubMedCrossRef An JY, Ha TK, Noh JH et al (2009) Proposal to subclassify stage IV gastric cancer to IVA, IVB and IVM. Arch Surg 144:38–45PubMedCrossRef
15.
go back to reference Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820PubMedCrossRef Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820PubMedCrossRef
16.
go back to reference Cunningham D, Rao S, Nicolson M et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46PubMedCrossRef Cunningham D, Rao S, Nicolson M et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46PubMedCrossRef
17.
go back to reference Okines AFC, Norman AR, McCloud C et al (2009) Meta-analysis of the REAL-2 and ML-17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 20:1529–1534PubMedCrossRef Okines AFC, Norman AR, McCloud C et al (2009) Meta-analysis of the REAL-2 and ML-17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 20:1529–1534PubMedCrossRef
18.
go back to reference Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221PubMedCrossRef Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221PubMedCrossRef
Metadata
Title
Surgical Impact on Gastric Cancer with Locoregional Invasion
Authors
Kuan-Kai Lai
Wen-Liang Fang
Chew-Wun Wu
Kuo-Hung Huang
Jen-Hao Chen
Su-Shun Lo
Anna Fen-Yau Li
Publication date
01-11-2011
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 11/2011
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-011-1246-9

Other articles of this Issue 11/2011

World Journal of Surgery 11/2011 Go to the issue